艾立布林治疗晚期乳腺癌的临床疗效分析  

Clinical efficacy of Eribulin in the treatment of advanced breast cancer

作　　者：魏玲[1] 王燕[1] 王培[2] 陈志敏[1] 王群[1] 魏卫[1] WEI Ling;WANG Yan;WANG Pei;CHEN Zhimin;WANG Qun;WEI Wei(Department of Medical Oncology,Xuzhou Central Hospital,Xuzhou 221009,China;Department of Breast Surgery,Xuzhou Central Hospital,Xuzhou 221029,China)

机构地区：[1]徐州市中心医院肿瘤内科,江苏徐州221009 [2]徐州市中心医院乳腺外科,江苏徐州221009

出　　处：《中国肿瘤外科杂志》2023年第1期36-39,共4页Chinese Journal of Surgical Oncology

基　　金：江苏省自然科学基金面上项目(SBK2018021825)。

摘　　要：目的分析艾立布林治疗晚期乳腺癌的临床疗效。方法选择2020年1月至2021年11月徐州市中心医院诊治的90例蒽环/紫杉类治疗失败的人类表皮生长因子受体2(HER-2)阴性晚期乳腺癌患者,以化疗方案不同将其分成分为观察组(n=40)、对照组(n=50)。对照组接受白蛋白结合型紫杉醇治疗,观察组接受艾立布林治疗。对比2组临床疗效、血清糖类抗原153(CA153)、癌胚抗原(CEA)水平、癌症患者生存质量量表(QLQ-C30)、不良反应及预后情况。结果观察组客观缓解率(27.50%)比对照组(10.00%)高(P<0.05),观察组疾病控制率(62.50%)比对照组(40.00%)高(P<0.05)。治疗后,2组血清CA153、CEA水平均降低(P<0.05),且观察组更低(P<0.05)。治疗后,2组QLQ-C30评分均升高(P<0.05),且观察组更高(P<0.05)。2组Ⅰ~Ⅳ级中性粒细胞减少、血小板减少、贫血、恶心、外周神经病变发生率比较差异无统计学意义(P>0.05)。随访1年,观察组失访1例,对照组失访2例,观察组中位无进展生存时间(PFS)均比对照组长(P<0.05)。观察组PFS曲线优于对照组(P<0.05)。结论艾立布林治疗晚期乳腺癌近远期疗效确切,可降低血清CA153、CEA水平,提高生存质量,且安全可靠。Objective To analysis the clinical efficacy of Eribulin in the treatment of advanced breast cancer.Methods A total of 90 advanced breast cancer patients with negative human epidermal growth factor receptor 2(HER-2)who failed the treatment of anthracycline/taxane in Xuzhou Central Hospital from January 2020 to November 2021 were selected and divided into observation group(n=40)and control group(n=50)according to different chemotherapy schemes.The patients in control group received Abraxane for injection.And the Eribulin was used in observation group.The clinical efficacy,serum carbohydrate antigen 153(CA153),carcinoembryonic antigen(CEA)levels,life quality(QLQ-C30),adverse reactions and prognosis were compared between the two groups.Results The objective remission rate of the observation group(27.50%)was higher than that of the control group(10.00%)significantly(P<0.05).And the disease control rate of the observation group was higher than that of the control group(62.5%vs.40%,P<0.05).After the treatment,the levels of serum CA153 and CEA in both groups decreased significantly(P<0.05),especially for the observation group(P<0.05).The QLQ-C30 scores of both groups increased(P<0.05),especially for the observation group(P<0.05).There was no difference in the incidence rates of grades I-IV neutropenia,thrombocytopenia,anemia,nausea and peripheral neuropathy between the two groups(P>0.05).After 1-year follow-up,1 case was lost to follow-up in the observation group and 2 cases in the control group.The median progression-free survival time(PFS)in the observation group was longer than that in the control group(P<0.05).Conclusions Eribulin has definite short-term and long-term efficacy in the treatment of advanced breast cancer,which reduces the levels of serum CA153 and CEA levels and improves the quality of life for patients.

关 键 词：艾立布林 晚期乳腺癌 临床疗效 安全性 

分 类 号：R737.9[医药卫生—肿瘤]